Mirum Pharmaceuticals (MIRM) Notes Payables (2020 - 2023)

Mirum Pharmaceuticals' Notes Payables history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2023.

• In Q1 2023, Notes Payables fell 45.39% year-over-year to $1.1 million; the TTM figure through Mar 2023 stood at $1.1 million (down 45.39% YoY), while the FY2022 annual figure was $1.1 million, down 45.39% from the prior year.
• Notes Payables for Q1 2023 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
• The five-year high for Notes Payables was $2.2 million in Q2 2021, with the low at $847000.0 in Q3 2021.
• The 4-year median for Notes Payables is $1.5 million (2020), against an average of $1.5 million.
• Peak annual rise in Notes Payables reached 114.62% in 2022, while the deepest fall reached 45.39% in 2022.
• Mirum Pharmaceuticals' Notes Payables stood at $1.3 million in 2020, then jumped by 57.91% to $2.0 million in 2021, then tumbled by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
• Business Quant data shows MIRM's Notes Payables at $1.1 million in Q1 2023, $1.1 million in Q4 2022, and $1.8 million in Q3 2022.